By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Topline Knowledge from OVATION 2 Trial Anticipated in Mid-2024 Imunon, Inc. (NASDAQ:IMNN) is at present conducting the Section 1/2 OVATION 2 trial of IMNN-001, the corporate’s IL-12 gene-mediated immunotherapy that’s primarily based on the TheraPlas expertise. The OVATION 2 examine is evaluating … Read more
Owen Silvera (pictured bottom-center) along with his analysis crew at Lake Okeechobee. Picture by Owen Silvera. Within the early mornings and late nights, from dawn to sunset, graduate scholar Owen Silvera and his colleagues launched into numerous expeditions in Lake Okeechobee. “I recall spending total days there, centered on gathering sediment in hopes to disclose … Read more
For over twenty years, I’ve predicted the tip of the ATM, money and playing cards. Lastly, lots of these predictions seem like coming true. It’s actually true of money versus card … … and now it’s turning out to be true for card versus pockets … Admittedly, the second image is from a cell funds … Read more
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Enterprise Replace XOLREMDI Permitted by the FDA On April 29, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced that the U.S. Meals and Drug Administration (FDA) has authorised XOLREMDI (mavorixafor) to be used in sufferers 12 years of age and older with WHIM syndrome (warts, … Read more